SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Following imatinib treatment in CML cell lines, SIRT1 expression was decreased, but not completely depleted (Yuan et al., 2012), providing a rationale for direct SIRT1 inhibition.